CSL (ASX:CSL) share price falls amid ongoing AstraZeneca uncertainty

The CSL (ASX:CSL) share price is slumping today as ongoing uncertainty over the side effects of the AstraZeneca vaccine continue.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are edging lower today as ongoing uncertainty over the side effects of the AstraZeneca COVID-19 vaccine continues. At the time of writing, the CSL share price is trading 0.11% lower at $265.22.

CSL is involved in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The company advised late last month it is set to produce more than 1 million doses of the AstraZeneca vaccine per week. 

It was commissioned by the government to produce 50 million doses of the AstraZeneca vaccine, before the vaccine was found to create a one-in-200,000 chance of blood clots – termed thrombosis with thrombocytopenia – around the brain and abdomen.

This led to the government's health body ruling out use of the vaccine for anyone under 50-years-old, including frontline health workers, but that uncertainty has led to the widespread cancellation of vaccine appointments across the country.

One Australian patient suffered thrombosis and a low platelet count after being vaccinated on 22 March.

The government has ordered an additional 20 million doses of the Pfizer vaccine, bringing the total to 40 million, which are due to arrive late this year.

This is leading to concerns that many of the vaccine doses CSL is producing will go to waste. Furthermore, the government has now thrown out any timeframe around rolling out the vaccine.

CSL said in a statement on 8 April that it was still committed to producing the AstraZeneca vaccine.

 "[CSL is] committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines."

"We will continue our focused and important efforts to manufacture this vaccine which remains critical for the protection of our most vulnerable populations."

CSL share price snapshot

Despite initial dips in the CSL share price as vaccine targets were changed and AstraZeneca uncertainty pervaded news headlines, the company's shares have continued to rise over the past month.

At the time of writing, the CSL share price is up by 0.74% this week and 3.66% over the past month.

However, it's worth noting that the company's shares have been slipping since the outbreak of the COVID-19 pandemic. Over the past 12 months, the CSL share price has lost around 19% and it's down around 12% against the healthcare sector during that same period.

Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is rising on big FDA news

Some big news is giving this stock a major lift on Thursday.

Read more »